摘要
前列腺癌的发病率和死亡率逐年升高,严重威胁男性健康。骨骼是前列腺癌最主要的转移部位,超过70%的晚期前列腺癌患者会发生骨转移和骨相关事件(SREs)。骨转移及其引发的SREs如脊髓压迫、病理性骨折等,严重影响患者的生活质量。在积极治疗原发病灶的同时,使用骨改良药物治疗骨转移预防SREs不可忽视。目前,前列腺癌骨转移尚无统一治疗方案,针对现阶段的诊疗现状,结合临床实践与国内外相关研究,中国抗癌协会泌尿男生殖系统肿瘤专业委员会制定了前列腺癌骨转移和骨相关疾病临床诊疗专家共识(2021版),以期为临床医师提供更为合理的前列腺癌骨转移多学科诊疗策略。
The morbidity and mortality of prostate cancer ascend yearly,which seriously threatens the health of the male population.Bone is the main metastasis site of prostate cancer,with bone metastases and skeletal-related events(SREs)occuring in more than 70%of patients with advanced prostate cancer.Bone metastases and the resulting SREs,such as spinal cord compression and pathological fracture,seriously affect the life quality of the patients.Although the active treatments of the primary disease is important,the application of bone-modifying agents to prevent SREs cannot be overlooked.However,there is no standard treatment procedure for the bone metastasis of prostate cancer at present.According to the clinical status,the Genitourinary Oncology Committee of Chinese Anti-cancer Association formulated this consensus,which integrated clinical evidence and real world clinical practices in China and abroad,to help clinicians make more accurate diagnosis and treatment for the bone metastases of prostate cancer with multidisciplinary strategies.
作者
中国抗癌协会泌尿男生殖系统肿瘤专业委员会
叶定伟
王弘恺
Genitourinary Oncology Committee of Chinese Anti-cancer Association;Ye Dingwei(不详;Department of Urology,Fudan University Shanghai Cancer Center,Department of Oncology,Fudan University,Shanghai 200032,China)
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2021年第10期1016-1026,共11页
Chinese Journal of Oncology
关键词
前列腺肿瘤
骨转移
骨改良药物
多学科诊疗
Prostate neoplasms
Bone metastasis
Bone-modifying drugs
Multidisciplinary strategies
